Slovak
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Strana 1 od 60 výsledky
Dengue hemorrhagic fever virus vaccine
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
FIELD OF THE INVENTION
The present invention relates to a dengue hemorrhagic fever virus vaccine and compositions thereof and methods of developing the vaccine, to generate an immunity against infection by dengue hemorrhagic fever viruses.
The following discussion of the background of the invention
Method of immunization against the 4 serotypes of dengue fever
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to a method for inducing protection against the 4 serotypes of dengue fever in a patient, comprising: (a) a first administration of a monovalent vaccine comprising a vaccinal virus of a first serotype of dengue fever, (b) a
Determination of risk of developing dengue hemorrhagic fever/dengue shock syndrome, methods and compositions therefor
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
INTRODUCTION
The present Dengue disease is caused by infection with dengue virus (DV), an arthropod-borne virus transmitted by mosquitoes. Dengue virus is classified in the Flaviviridae family, genus Flavivirus. DV has been subdivided into 4 serotypes, DEN-1. DEN-2, DEN-3, and DEN-4.
Dengue virus is
Methods and biomarkers for the detection of dengue hemorrhagic fever
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
Dengue remains an international public health problem affecting urban populations in tropical and sub-tropical regions, where it is currently estimated that about 2.5 billion people are at risk of dengue infection. Dengue virus is a single positive-stranded RNA virus of
Adenoviral vector-based dengue fever vaccine
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY
Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 60,213 bytes ASCII (text) file named "713667_ST25.txt,"
Method and biomarkers for the detection of dengue hemorrhagic fever
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND
Dengue virus (DENV) infection remains an international public health problem affecting urban populations in tropical and sub-tropical regions, where it is currently estimated that about 2.5 billion people are at risk. Dengue virus is a single positive-stranded RNA virus of the family
Methods for treating immune-mediated Dengue Fever infections and antibody-dependent enhancement of Dengue Fever infections, including Dengue Hemorrhagic Fever and Dengue Shock Syndrome
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
TECHNICAL FIELD
This document relates to inhibition of immune complex formation associated with viral infection. For example, this document provides materials and methods for inhibiting immune complex formation in Dengue Fever (DF) infections and antibody-dependent-enhancement (ADE) of DF
Host targeted inhibitors of dengue virus and other viruses
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
Dengue virus (DENV) is one of the most significant mosquito-borne viral infections affecting humans today and is an NIAID (National Institute of Allergy and Infectious Diseases) Category A Biodefense pathogen. DENV is a plus-stranded RNA virus and a member of the
Antiviral drugs for treatment or prevention of dengue infection
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
FIELD OF THE INVENTION
This invention relates to the use of benzenesulfonamide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral diseases associated with the flavivirus family such as Dengue fever, Yellow fever, West Nile, St. Louis
Antiviral drugs for treatment or prevention of dengue infection
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
FIELD OF THE INVENTION
This invention relates to the use of benzenesulfonamide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral diseases associated with the flavivirus family such as Dengue fever, Yellow fever, West Nile, St. Louis
Subunit immonogenic composition against dengue infection
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
TECHNICAL FIELD
The invention relates to protection against and diagnosis of dengue fever. More specifically, the invention concerns a subunit of the dengue virus envelope protein secreted as a mature recombinantly produced protein from eucaryotic cells which is protective against dengue infection,
Treatment and prevention of dengue virus infections
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
FIELD OF THE INVENTION
This invention relates to the use of 2-aryl-benzothiazole or 2-heteroaryl-benzothiazole derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral diseases associated with the flavivirus family such as Dengue fever, Yellow
Dosing regimens of celgosivir for the treatment of dengue
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
Globally, dengue infections result in more than 20,000 deaths, nearly 500,000 hospitalized cases and anywhere between 50-100 million human infections annually. (1) Dengue infection is caused by one of four immunologically distinct serotypes of the dengue virus (DENV 1-4).
Dosing regiments of celgosivir for the treatment of dengue
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
Globally, dengue infections result in more than 20,000 deaths, nearly 500,000 hospitalized cases and anywhere between 50-100 million human infections annually. (1) Dengue infection is caused by one of four immunologically distinct serotypes of the dengue virus (DENV 1-4).
Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
Dengue viruses (DENV), members of the genus Flavivirus, are the most common cause of mosquito-borne viral diseases in tropical and subtropical regions around the world. Approximately 50 to 100 million people per year are infected with DENV. DENV infections may be
Najkompletnejšia databáza liečivých bylín podporovaná vedou
- Pracuje v 55 jazykoch
- Bylinné lieky podporené vedou
- Rozpoznávanie bylín podľa obrázka
- Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
- Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
- Vyhľadajte liečivé byliny podľa ich účinkov
- Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi
Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume
